Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

March 9, 2020March 9, 2020

Prolaris Test Predicts Which PC Patients Benefit from Combo Therapy, Study Finds

News

Myriad Genetics’ Prolaris — a genetic test that predicts the aggressiveness of prostate cancer — can identify which men with intermediate or high-risk prostate cancer will benefit from combining androgen ... Read more

March 4, 2020March 4, 2020

Genetic Test Seen to Predict Patients Helped by ADT Use After Surgery

News

A genetic test, called Decipher Prostate RP, can help to identify those prostate cancer patients with a relapse after surgery who will benefit most by adding androgen deprivation therapy (ADT) to radiation therapy, ... Read more

February 27, 2020February 27, 2020

Decipher GRID ‘Signature’ Predicts Chemo Benefits in HSPC, Research Shows

News

Decipher Bioscience’s proprietary artificial intelligence platform, Decipher GRID, one of the world’s largest urologic cancer genomic databases, can be used to identify subtypes of prostate cancer and predict which men ... Read more

February 19, 2020February 19, 2020

Onvansertib’s Addition Aids Responses to Zytiga Even in Resistant Patients, New Trial Data Show

News

Trovagene’s investigational oral therapy onvansertib helps overcome resistance to Zytiga (abiraterone acetate) in men with metastatic castration-resistant prostate cancer (mCRPC), latest data from a Phase 2 clinical trial show. These results also highlighted ... Read more

February 11, 2020February 13, 2020

Xtandi Significantly Improves Overall Survival in Men with High-risk CRPC, Phase 3 Final Data Show

News

Treatment with Xtandi (enzalutamide) significantly extends the lives of men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC), according to final data from a Phase 3 clinical trial. Developed by Pfizer and Astellas Pharma, Xtandi ... Read more

January 23, 2020January 23, 2020

Exelixis to Expand Group of mCRPC Patients in Phase 1b Trial Testing Cabometyx-Tecentriq Combo

News

Exelixis will expand its Phase 1b clinical trial evaluating a combination of Cabometyx (cabozantinib) with Tecentriq (atezolizumab) to include more patients with metastatic castration-resistant prostate cancer (mCRPC), based on preliminary ... Read more

January 16, 2020January 16, 2020

Rubraca Granted FDA Priority Review for Advanced Prostate Cancer with BRCA Mutations

News

The U.S. Food and Drug Administration (FDA) has granted priority review to Clovis Oncology’s application seeking approval of Rubraca (rucaparib) for treating men with recurrent metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations. The priority review status ... Read more

January 13, 2020January 13, 2020

Veyonda Plus Low-dose Radiotherapy May Halt Disease Progression in Late-Stage PC, Study Suggests

News

Noxopharm’s Veyonda (idronoxil), in combination with low-dose radiation therapy, safely halted disease progression and eased pain in men with late-stage metastatic castration-resistant prostate cancer (mCRPC), according to results from a Phase 1b clinical ... Read more

December 30, 2019January 9, 2020

PyL Imaging Agent Accurately Detects Recurrent Prostate Cancer Lesions, Trial Shows

News

Progenics Pharmaceuticals’ PyL, a new imaging agent for positron emission tomography (PET) scans, can accurately detect the location of recurrent prostate cancer lesions, according to data from a Phase 3 clinical trial. “The ... Read more

December 19, 2019December 19, 2019

Lynparza Particularly Effective in Prostate Cancer Patients Carrying BRCA Mutations, Phase 2 Study Shows

News

Lynparza (olaparib), a breast and ovarian cancer treatment, is also showing promising results in men with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in DNA repair genes, particularly the BRCA1 ... Read more